By: Israel Galmor
CEO
Share

OmegaMore

OmegaMore developed cutting edge bio-tech products to help treat & prevent chronic cognitive diseases such as Alzheimer‘s, dementia & ADHD, with a unique formula of high-concentration omega 3 DHA supplement. Its industry shows high growth with many M&A‘s.

$98,771

Raised so far

10

Investors

0

Days to go
Type:Equity   
Stage:Pre-seed
Category:Healthcare
•  Successfully funded    
  • Campaign Highlights
  • Pitch
  • Team
  • Investors 10
  • Updates 1

Campaign Highlights

A breakthrough development in Alzheimer's care

OmegaMore is a biotech company that develops, manufactures and markets omega-3 supplements extracted from sea algae. The company has developed a breakthrough product based on an innovative formula with essential components for the treatment and prevention of cognitive diseases such as Alzheimer's, depression and ADHD, as well as a wide range of heart and liver malfunctions, metastatic cancer and more. 

Great economic potential - an innovative product in a market estimated at tens of billions of dollars a year

The global omega-3 market is estimated at close to $ 35 billion a year and growing steadily. This is due to an increased understanding of the supplement's importance in preventing many diseases that have already become an epidemic in the Western world such as Alzheimer's, depression and ADD / ADHD. The innovative products based on OmegaMore's advanced chemical formula place the company at the forefront of a huge and growing market.

 

Personal life experience leads to a biotechnological breakthrough

The personal experience of the company's founder, Israel Glamor, with his family's close encounter with cancer, made him determined to study the disease and understand it in depth. These unfortunate circumstances led him to many years of intensive biological and chemical research, which eventually led to a biotechnological breakthrough that changes our ability to deal with a wide range of devastating diseases.

 

An experienced team with high-performance capabilities and rich a history in the field of biotech development

OmegaMore's team consists of experts with over 20 years of experience in the biotech and tech market, including the development formulas purchased by Teva. The company's founder, Israel Gelmor, is an expert in the field of fatty acids and has many years of experience in developing unique chemical formulas and innovative products for some of the largest pharma companies in the market.

Pitch

The idea

Omega-3 is essential to the body's daily functioning. The body is not able to create its own Omega-3 fatty acids and therefore must consume it from animals and plants.

Chronic brain disorders impair a growing portion of Western society as a result of poor dietary habits and lifestyle. ADD and ADHD among children are a prominent example. Yet, since children cannot, or will not, swallow capsules, we have developed a liquid algae product of DHA Omega-3, with strawberry and vitamin D supplements available to children of all ages.

Many adults and elderly also have trouble swallowing capsules, and so the product OmegaMore offers is also suitable for said adults’ daily consumption. Many studies have shown the benefits of using DHA to treat depression, anxiety, and even Alzheimer's Disease, which has become a 21st century’s epidemic due to increased longevity.

Alzheimer's Disease

Alzheimer's Disease is the sixth largest cause of death in the United States. For comparison, 1 out of every 3 seniors dies from Alzheimer's, so the disease kills more Americans each year than prostate cancer and breast cancer combined! About 5.7 million (2018) Americans suffer from it, and by 2050 it is estimated that this number will reach 14 million. The cost of treating cognitive diseases is estimated to have reached $277 billion in 2018.

(Israel currently has 200,000 Alzheimer's patients, most of whom do not have treatment frameworks).

cardiovascular diseases

 cardiovascular diseases continue to be one of the leading causes of death in the Western world, responsible for 1 of every 3 deaths in the US (2018).

According to many studies, Omega-3 deficiency in general, and DHA deficiency in particular is the main cause of brain disorders and the formation of infections that cause heart disease.

 

 

Additional factors that support the need for Omega-3 in general and Algae DHA in particular:

 Increasing Demand for "Functional Food" - food enhanced with essential supplements (a $44 billion market in the US as of 2012), as well as continued awareness of the issue and increased consumption of food considered to have health benefits.

Over-Fishing - diminishing fish population due to overfishing, and pollution due to ocean acidification, coupled with the process of purification of Omega-3 from fish and detoxification from heavy metals, increases the cost of producing Omega-3 from fish, which is then passed on to the consumer at the product’s end. This creates a need to find a different source for the Omega-3 production, such as algae, especially since this is an essential substance that cannot be produced by the human body.

A Global Increase in Vegetarian, Vegan, and Organic Food Intake – Omega-3 produced from algae allows people who cannot consume a fish-based and/or krill (small crab) supplement, such as vegans and vegetarians, to still be able to consume Omega-3. Moreover, the active ingredient, DHA, does not exist in dry-land plants, and thus cannot be consumed from other sources.

“Around 85% of global fish stocks are over-exploited, depleted, fully exploited or in recovery from exploitation.”

BBC, Sep 12                                                      

“Omega 3 Ingredients Market to Witness Rapid Growth thanks to Heightened Awareness Regarding Benefits of Omega 3 Fatty Acids; Industry Analysis & Trends 2021...”

CNBC, June 16

 

 

The solution   

Develop unique nutritional supplements based on DHA Omega-3 made from microalgae. These will help improve quality of life by preventing and blocking the development of most brain disorders, cardiovascular diseases, and even alleviating existing illnesses by increasing the Omega-3 fatty acids concentration in red blood cells.

 

The company’s goal is to significantly reduce illnesses typical of the western world – cancer and metastasizes, cardiovascular diseases, liver diseases, brain disorders such as ADD, Epilepsy, Schizophrenia, depression, anxiety, Multiple Sclerosis, Alzheimer's and Parkinson's, fertility issues (especially in men),  and improper fetus development.

 

Israel Glamor, an expert in the field of fatty acids, who has been developing innovative formulas for the past 20 years, including for the largest pharma companies in the market, has developed a unique formula of Omega-3 from sea algae named DHA Premium.

 

The formula contains a high concentration of DHA Omega-3 fatty acids produced directly from algae, alongside vitamin D3 and natural grapefruit and strawberry essence.

 

Science & Technology

OmegaMore develops grows and cultivates unique algae in laboratories and in clean pools. The company's unique extraction process of DHA Omega-3 yields a concentration of 40-45%, significantly higher than most of the competition. This is particularly important due to the fact that DHA is the main component of adipose tissue in the human brain and is responsible for maintaining the normal functioning of the brain.

International Credentials - The company's products comply with the following international standards: FDA (USA) and GMP (International), as well as European quality approval of NOVEL FOOD and SGS Laboratories worldwide. OmegaMore also has a Kosher certificate from Badatz (Eda Hachareidis Jerusalem).

Patentability - The company's new and improved product is expected to be released in 2019, and is based on a unique formula. The company will be able to apply for a patent for this product, and it is estimated to double or even triple the company’s current sales (rough assessment).

The Differences between Algae-based Omega-3, and Fish/Krill Oil Omega-3 - Both fish and krill feed on algae to create omega-3, and thus by producing Omega-3 directly from those algae we can skip an entire stage along the way and reduce costs.

Most of the brain tissue is fatty tissue, and 30% of it (in a healthy brain) is made of DHA Omega-3 fatty acids, which can be obtained only from the "marine" sources (fish and seaweed), and not dry land sources. In addition, DHA comprises about 93% of the Omega-3 composition in the eye’s retina.

 

The algae are grown in freshwater ponds to which salts and minerals are added - In this way, we can simulate the natural environment of algae but avoid exposure to pollution and heavy metals that are present in the sea.

The existing product is currently sold as a grapefruit-strawberry flavored liquid with vitamin D and is suitable for kids and the elderly as well. In addition, OmegaMore will expand its range of products next year with strawberry chewable capsules and with plain capsules for all age groups.

Seaweed oil and powder are currently in advanced stages of development. These will be used for enriching various food products such as dark chocolate, tahini, and olive oil.

The company is also in the initial stages of development of DHA powders for the enrichment of animal food mixtures (intended for completion in 2020).

 

OmegaMore in the media

 

 

Article about OmegaMore's presenter, Nancy Brandes

 

Article from NewsIL

 

Second article from NewsIL

 

Article in Health&Wellness

 

Article in Smart-Life

 

Article in "Health" magazine

 

Article in TheMarker

 

Article in "Mint" magazine

 

Second article in "Mint" magazine

 

Thirth atricle in "Mint" magazine

 

Team

Israel Galmor
Founder & CEO
Biography
Israel is an experienced CEO with some 20 years of cumulative experience as CEO of Omegal and OmegaMore, both of which he has founded. Israel is also an expert chemist and developer of fatty acids formula, developing formulas in the food supplements industry for some of the leading companies in the market such as Teva. Israel has a B.A from Bar-Ilan University.

  • Founder
Ofer Taran
CMO & Sales Director
Biography
Opher has a 25 years experience in international project marketing management and business development, as well as brand and OEM development. Opher gained his experience at a number of bio-med and pharma startup companies, as well as in corporations such as Orbotech (England), Minicom (Singapore), and as the founder and CEO of Biosan Medical in past 12 years. Opher has a B.Sc. in electrical engineering from Tel-Aviv University, and an international marketing diploma from Xerox Corporation.

  • Key Employee
Yossi Gabbay
CFO
Biography
Yossi held the position of CEO and CFO in a number of companies, including as CFO of the Shomera insurance company Ltd. (with a 40 million exit deal) for 10 years, and as the CEO of Shahar Hadash Group Ltd (a publicly traded company until recently) for the past 15 years.

  • Key Employee
Adam Galmor
CTO & Director of IT
Biography
Adam is a highly experienced Software Engineer and has worked for some of the market‘s leading software companies such as Checkpoint and Radware. As the company adds E-commerce, Adam will develop and manage its IT and database (Costumers, suppliers etc.), and will be responsible for data security, etc. Adam has a B.Sc. in computer science and an M.B.A from Tel-Aviv University, both cum laude, as well as a B.A in mathematics and life sciences from H.I.T College – cum laude.

  • Director
Jason Barzilay
Advisory Board Member
Biography
Jason Barzilay was the co-founder, a large shareholder, and an Executive Director of Packard Bell, which was the world‘s largest personal computer maker between 1986-1998 (units sold). Jason and his two founding partners sold their holdings to NEC in 1998 Presently, Mr. Jason Barzilay (Founder) serves as an Executive Director at Dragon Ventures Management, a HK registered company offering complete solutions for Israeli companies wishing to establish a presence in Greater China.

  • Advisor

Investors 10

Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
2
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
7
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments

Updates 1

  • Update date: 21/02/2019
    We are pleased to announce that Nansi Brandes has joined Omegamore's team. He is an Israeli famous musician and entertainer. We are experiencing increased demand for the company's products in Israel as well as overseas distributors, and are preparing for increased production. To accommodate this, we signed an agreement with Lycoris, which produces the highest quality standards, with the following approvals: GMP, HACCP, the Israeli ministry of health as well as a Hasidic Kosher seal of approval.

The Deal

Documents

Disclosures

The financing rounds made through the ExitValley platform are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) to the Israeli companies law - 1965.
Under our model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors which are not qualified investors and the round of financing in not in the format of an offering arrangement ("רכז הצעה") as defined in the securities law
Follow us